compiling this information would not be commensurate with the results likely to be achieved. However, it is stated that prices of Scheduled medicines are fixed in accordance with the provisions of DPCO, 1987 after careful scrutiny of the recommendations of BICP, an expert Government body on Industrial Costs and Prices. This mechanism ensures that the increase in prices is corelated with the actual increase in the input costs.

In case of non-scheduled medicines, on the basis of a sample, analysis, it has been found that in 12-13% cases the prices have recorded an increase of more than 100% over their prices prevailing at the time of announcement of DPCO, 1987.

- (d) No; Sir. However, monitoring is done to the extent possible.
- (e) A statement is enclosed. However, in view of profitability of the pharmaceutical units being generally below the levels prescribed in Scheduled V of DPCO_T 87, Government's ability to intervene in pricing of non-scheduled formulations gets sewhat restricticted.

Statement

| SI. No. | Name of the Company | Name of the formulation | | Pack Price size fixed by the Company | | Effective% De reas | |
|------------|------------------------|-------------------------|------------|---|--------|--------------------|-------|
| 1 | 2 | _ 3 | | 4 5 | 6 | 7 | 8 |
| 1. | ALEMBIC | Pethidine Inj. | 2ml×10 Amp | . 37.54 | 33.00 | 30.11.90 | 12.09 |
| 2. | ALEMBIC | Morphine Inj. | 1ml×12 Amp | . 37.04 | 29.00 | 30.11.90 | 21.71 |
| 3. | INDO-PHARMA | Carbindra Strong | Tabs 100 | s 40.00 | 35.00 | 26.3.91 | 12.50 |
| 4. | SERDIA PHARMA | Natrilin . | 100 | s 39.62 | 32.07 | 16.12.91 | 19.05 |
| 5. | SERDIA PHARMA | Ponderan 60mg. | 10` | s 68.73 | 61.16 | 16.12.91 | 11.01 |
| 6. | HINDUSTAN CIBA-GEIGY | Deoferal Inj. | 5 vial | s 410.00 | 290.00 | 01.03.92 | 29.27 |

Survey On Fertilizer Corporation of India

3607. SHRI RAM RATAN RAM: DR. NAUNIHAL SINGH: DR. MURLI MANOHAR JOSHI: SHRI S.K.T. RAMA-CHANDRAN:

Will the PRIME MINISTER be pleased to state:

- (a) what is the accumulated loss of the Fertilizer Corporation of India as on March 31, 1992;
- (b) what is the loss incurred or profit gained by the Corporation during 1991-92 and the first six months of 1992-93;
- (c) what steps have been taken by Government to make the Fertilizer Corporation of India a viable and profit making undertaking;
 - (d) whether any survey has been made

- on the sickness of the Corporation; and if so, what are the findings;
- (e) what are the month-wise production of urea and other chemical fertilizers in each of the unit of the Corporation in 1992; and
- (f) whether the Talcher and Ramagundam units have shown any profitable trend?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) The accumulated loss of the Fertilizer Corporation of India (FCI) as on 31st March, 1992 was Rs. 1610.78 crores. After adjustment for prior period, the company incurred a net loss of Rs. 225.41 crores during the year 1991-92. The loss for the first six months of 1992-93 is estimated at Rs. 161.76 crores.

(c) and (d) Based on regular

performance appraisals of the company.

it has been found that the company

has incurred losses mainly on account

of poor capacity utilisation arising from

66

During the current financial year, FCI has been provided non-plan budgetary support of Rs. 18.74 crores by the Government to meet the working capital needs and other liabilities

Government to the working capital other liabilities despite the severe budgetary constraints. The company is also being paid its subsidy dues regularly. In addition, its Ramagundam and Talcher units have been given extra allowance consumption norms & capacity utilization under the Retention Price-

(e) The month-wise production of urea in each of the units of FCI during the calender year 1992 are as

cum-subsidy Scheme in view of the

vintage of these plants.

equipment design deficiencies. prolonged power cuts, non-availability of raw materials and spares due to severe fund constraints, etc. FCI has submitted proposals for rehabilitation/ ravamp of its various units, as also proposal for restructuring of FCI. Since these proposals involve heavy budgetary support from Govt.. decision has been taken. Meanwhile, the company has been declared as sick by the Board for Industrial Financial Reconstructions (BIFR) with a direction to the Government to present a revival package by 31.3.1993.

Production
UREA (000 MT)

under:-

| Month | Sindri | Gorakhpur | Ramagundam | Talcher |
|----------|--------------|-----------|--------------|------------|
| Jan. 92 | 25.7 | Nil | 22.3 | 11.4 |
| Feb. 92 | 26.3 | Nil | $\bar{19.0}$ | 10.0 |
| Mar. 92 | 31.6 | Ñil | 19.5 | 13.0 |
| Apr. 92 | 19.5 | Nil | 0.210 | Nil |
| May 92 | 15.4 | Nil | Nil | Nil |
| June. 92 | 19.9 | Nil | Nil | Nil |
| July. 92 | 25.1 | Nil | Nil | Nil |
| Aug. 92 | $\bar{18.0}$ | Nil | 10.8 | Nil 5.4 |
| Sept. 92 | 14.1 | Nil | 15.2 | 11.4 |
| Oct. 92 | 33.2 | Nil | 18.6 | 12.6 |
| Nov. 92 | 30.6 | Nil | 16.7 | 16.2 |
| NOV. 92 | 30.0 | NII | 10.7 | 10.2 |

(f) No, Sir.

Production of drugs in genetic name

3608. SHRI B. K. HARIPRASAD:
SHRI ABDUL SAMAD
SIDDIQUI:
SHRIMATI KAILASHPATI:
DR. FAGUNI RAM:

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Companies like Roussel, Hoechst. Cadila. Glaxo. German Remedies. Alembic. Fairdeal and others are their drug formulations in association with Small Scale Sector units in genetic names to escape from price control under DPCO, 1987;

- (b) whether it is a fact that no such recommendation was made by the Kelkar Committee;
- (c) if so, what are the names of formulations being marketed by each of them in association with SSI units;
- (d) what are the details of the products sold in such association prices charged at present pack-wise and the extent of overcharging;
- (c) what are the names of bulk drugs on which each product is based